Skip to content

SCLX

Scilex Holding Co

NASDAQ · Healthcare · Drug Manufacturers - General · US

$2.05
−1.91%
Ask drillr

Year over year

Reported trailing growth

Revenue
-28.5%
EBITDA
—
EBIT
—
EPS
—
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
+399.3%
EBITDA
+108.4%
EPS
+100.4%

Three-year CAGR

Revenue
-7.3%
EBITDA
—
EBIT
—
Net income
—
EPS
-87.8%
Free cash flow
-80.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026